Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331773 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,116
- Enrollment target
NCT00331773: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.
NCT00331773 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,116 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00331773, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,116 participants
- Enrollment target
Study Summary
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving hypofractionated radiation therapy (higher doses over a shorter period of time), may be less costly with fewer side effects and just as effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying several different radiation therapy regimens to compare how well they work in treating patients with stage II prostate cancer.
Primary Outcome
Five-year rates are estimated by the Kaplan-Meier method. DFS events included local progression, distant metastatic progression, biochemical recurrence as defined by the Radiation Therapy Oncology Group (RTOG) Phoenix definition, or death from any cause. Patients who experienced second primary cancers remained under observation for DFS events.
Interventions
- RADIATION Conventional 3D-CRT or IMRT
- RADIATION Hypofractionated 3D-CRT or IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,116 participants |
| Start Date | 2006-04 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 3 |
What the finished NCT00331773 record still lists
NCT00331773 is an interventional study that assigns participants to a tested intervention. Its 1,116 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 2 interventions - of which Conventional 3D-CRT or IMRT is the first listed.
NCT00331773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00331773 about?
NCT00331773 is a clinical study titled "Radiation Therapy in Treating Patients With Stage II Prostate Cancer". RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving hypofractionated radiation therapy (higher doses over a shorter period of time), may be less costly with fewer side effects and just as effec...
What is the current status of trial NCT00331773?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,116 participants. The study started on 2006-04. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT00331773?
The interventions under investigation include: Conventional 3D-CRT or IMRT (RADIATION), Hypofractionated 3D-CRT or IMRT (RADIATION).
Who is sponsoring clinical trial NCT00331773?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00331773's enrollment target sits among peer trials
1,116 251st of 2000 higher than 1,750 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia